In primary breast cancers and preinvasive lesions, an aberrant KEAP1 promoter methylation was seen to be more recurrent in ER-positive, HER2-negative than in triple-negative breast cancers and was hypothesized to be a prognostic marker since a higher mortality risk in triple-negative patients was predicted. Here, KEAP1 is linked to breast cancer.